These innovative molecules represent a significant leap in the management of type 2 diabetes. Retatrutide, a dual GLP-1 and GIP receptor agonist, demonstrates remarkable efficacy in lowering blood glucose levels. https://louiseqsyr462932.bloginder.com/39809071/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide